Table 1 Demographic and clinicopathological characteristics
Characteristics | levels | Centre I (n = 532) | Centre II (n = 113) | Centre III (n = 185) | Centre IV (n = 381) | TCIA (n = 99) | Duke (n = 226) |
|---|---|---|---|---|---|---|---|
ALN burden | Low | 448 (84.2%) | 90 (79.6%) | 149 (80.5%) | 309 (81.1%) | NA | NA |
High | 84 (15.8%) | 23 (20.4%) | 36 (19.5%) | 72 (18.9%) | NA | NA | |
ALN status | Negative | 272 (51.1%) | 62 (54.9%) | 119 (64.3%) | 218 (57.2%) | NA | NA |
Positive | 260 (48.9%) | 51 (45.1%) | 66 (35.7%) | 163 (42.8%) | NA | NA | |
Menopausal Status | Postmenopausal | 241 (45.3%) | 52 (46%) | 124 (67%) | 297 (78%) | NA | NA |
Premenopausal | 291 (54.7%) | 61 (54%) | 61 (33%) | 84 (22%) | NA | NA | |
Histological grade | Low | 34 (6.4%) | 9 (7.9%) | 14 (7.6%) | 45 (11.8%) | NA | NA |
Intermediate | 313 (58.8%) | 35 (31.0%) | 88 (47.6%) | 130 (34.1%) | NA | NA | |
High | 185 (35.8%) | 69 (61.1%) | 83 (44.9%) | 206 (54.1%) | NA | NA | |
Histological type | Ductal | 494 (92.9%) | 100 (88.5%) | 165 (89.2%) | 341 (89.5%) | NA | 207 (91.6%) |
Lobular | 12 (2.3%) | 3 (2.7%) | 4 (2.2%) | 14 (3.7%) | NA | 16 (7.1%) | |
Other | 26 (4.9%) | 10 (8.8%) | 16 (8.6%) | 26 (6.8%) | NA | 3 (1.2%) | |
Enhanced pattern | Mass | 418 (78.6%) | 91 (80.5%) | 140 (75.7%) | 305 (80.1%) | NA | NA |
No-mass | 114 (21.4%) | 22 (19.5%) | 45 (24.3%) | 76 (19.9%) | NA | NA | |
MRI ALN status | Negative | 405 (76.1%) | 88 (77.9%) | 164 (88.6%) | 296 (77.7%) | NA | NA |
Positive | 127 (23.9%) | 25 (22.1%) | 21 (11.4%) | 85 (22.3%) | NA | NA | |
MRI ALN burden | Low | 505 (94.9%) | 104 (92%) | 174 (94.1%) | 358 (94%) | NA | NA |
High | 27 (5.1%) | 9 (8%) | 11 (5.9%) | 23 (6%) | NA | NA | |
Ki67 (%) | <14 | 135 (25.4%) | 29 (25.7%) | 49 (26.5%) | 139 (36.5%) | NA | NA |
≥ 14 | 397 (74.6%) | 84 (74.3%) | 136 (73.5%) | 242 (63.5%) | NA | NA | |
ER | Negative | 85 (16%) | 35 (31%) | 57 (30.8%) | 112 (29.4%) | NA | 56 (24.8%) |
Positive | 447 (84%) | 78 (69%) | 128 (69.2%) | 269 (70.6%) | NA | 170 (75.2%) | |
PR | Negative | 120 (22.6%) | 34 (30.1%) | 69 (37.3%) | 121 (31.8%) | NA | 74 (32.7%) |
Positive | 412 (77.4%) | 79 (69.9%) | 116 (62.7%) | 260 (68.2%) | NA | 152 (67.3%) | |
HER2 | Negative | 417 (78.4%) | 63 (55.8%) | 107 (57.8%) | 278 (73%) | NA | 190 (84.1%) |
Positive | 97 (18.2%) | 30 (26.5%) | 34 (18.4%) | 70 (18.4%) | NA | 36 (15.9%) | |
Uncertainty | 18 (3.4%) | 20 (17.7%) | 44 (23.8%) | 33 (8.7%) | NA | NA | |
Molecular subtype | Luminal | 456 (85.9%) | 80 (74.1%) | 134 (78.8%) | 277 (76.5%) | NA | NA |
HER2-positive | 35 (6.6%) | 17 (15.7%) | 18 (10.6%) | 32 (8.8%) | NA | NA | |
Triple-negative | 40 (7.5%) | 11 (10.2%) | 18 (10.6%) | 53 (14.6%) | NA | NA | |
Clinical Tumor stage | T1 | 206 (38.7%) | 51 (45.1%) | 75 (40.5%) | 150 (39.4%) | 43 (43.4%) | 128 (56.6%) |
T2 | 326 (61.3%) | 62 (54.9%) | 110 (59.5%) | 231 (60.6%) | 56 (55.6%) | 98 (43.4%) | |
Age | Median (IQR) | 50.00 [44.00, 59.00] | 51.00 [44.00, 60.00] | 56.00 [49.00, 68.00] | 53.00 [46.00, 62.00] | 53.00 [45.00, 62.00] | NA |